AT THIS HOUR

1: No not the U2 song about love but the drug that is getting everyone’s attention—the question is not IF but WHEN GLP-1s will meaningfully reduce the number of patients needing acute care, chronic care management, imaging, PT, addiction treatment and surgery – there are indications the drug is making an impact, but just how wide scale will this be and will the drug reduce the pool of eligible patients coming into your practice?  We’re convening a panel of clinical thought leaders Jan. 21st to talk about the cascading effect of GLP-1s. To register, click here.

Science: There’s a misnomer about borderline personality disorder - the answer here.

Sport: Here’s a clip from one of the runners in the Boston Bulldogs documentary Cannes World Film Festival named Best Student & Health Film in 2024 for its depiction of resilience amidst addiction recovery.

Policy: Expect some pushback on the endless series of visits you, your relatives and your kids might get for behavioral health therapy next year. Insurer Highmark BlueCross BlueShield from Pennsylvania, Delaware, West Virginia and New York will start to require pre approval for 19 distinct services including applied behavioral analysis for autism, intensive outpatient therapy, and transcranial magnetic stimulation or TMS which takes places over 30 sessions to address OCD and depression.  

Poll: Take our survey for a gift card - it’s on the topic of low-T, a condition affecting both men and women. Click here.

Perspective: The dog died a year ago today….he was a pain in the butt a lot of the time but I miss seeing that barker in the window…

Read the archives